HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Methylthioinosine

6-(Methylthio)-9-beta-D-ribofuranosylpurine. An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
Also Known As:
6-Methylthiopurine Riboside; 6 Methylmercaptopurine Riboside; 6 Methylthiopurine Riboside; Riboside, 6-Methylmercaptopurine; Riboside, 6-Methylthiopurine; 6-Methylmercaptopurine Riboside; Inosine, 6-S-methyl-6-thio-
Networked: 19 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Bernard, Kristen A: 1 article (01/2011)
2. Striker, Rob: 1 article (01/2011)
3. Keating, Julie A: 1 article (01/2011)
4. Hoover, Spencer: 1 article (01/2011)
5. Lim, Pei-Yin: 1 article (01/2011)
6. Koutcher, J A: 1 article (02/2001)
7. Martin, D S: 1 article (02/2001)
8. Spriggs, D: 1 article (02/2001)

Related Diseases

1. Neoplasms (Cancer)
02/01/1968 - "Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercaptopurine riboside (NSC-40774) in patients with acute leukemia and metastatic cancer."
09/04/1991 - "Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens."
08/01/1992 - "High performance liquid chromatography and nuclear magnetic resonance spectroscopy measurements of biochemical changes resulting from treatment with N-(phosphonacetyl)-L-aspartate plus 6-methylmercaptopurine riboside plus 6-aminonicotinamide indicated a severe depletion of cellular energy levels in the treated tumors. "
01/01/1994 - "A quadruple drug combination--consisting of a triple-drug combination of N-(phosphonacetyl)-L-aspartate (PALA) + 6-methylmercaptopurine riboside (MMPR) + 6-amino-nicotinamide (6-AN), designed to primarily deplete cellular energy in tumor cells, + Adriamycin (Adria)--yielded significantly enhanced anticancer activity (i.e., tumor regressions) over that produced by either Adria alone at maximum tolerated dose (MTD) or by the triple-drug combination, against large, spontaneous, autochthonous murine breast tumors. "
12/01/1997 - "To evaluate the effects of biochemical modulation by N-(phosphonacetyl)-L-aspartate (PALA), 6-methylmercaptopurine riboside (MMPR), and 6-aminonicotinamide (6AN), (PALA + MMPR + 6AN is referred to as PMA) on tumor radiosensitivity, and evaluate the efficacy of the addition of 5-FU to the PMA + XRT regimen for enhancement of tumor response to radiation without exceeding normal tissue tolerance. "
2. Leukemia
3. Pancreatic Neoplasms (Pancreatic Cancer)
4. Neuroblastoma
5. Hepatocellular Carcinoma (Hepatoma)

Related Drugs and Biologics

1. NSC 224131 (PALA)
2. Fluorouracil (Carac)
3. 6-Aminonicotinamide (6 Aminonicotinamide)
4. 6-Mercaptopurine (Mercaptopurine)
5. purine
6. Vincristine (Oncovin)
7. Methionine (L-Methionine)
8. Cytarabine (Cytosar-U)
9. Cyclophosphamide (Cytoxan)
10. 5'-methylthioinosine

Related Therapies and Procedures

1. Transplants (Transplant)